Subscribe To
Fmls:23 speaker spotlight – art of autonomy: tailored tech for tomorrow’s brokerage
Technological advancements continue to reshape the way retail brokerages operate and deliver services in 2023. The pace of this technological adoption...
October 18, 2023, 11:47 am
A packed agenda of six federal reserve speakers coming up wednesday, along with beige book
A barrage of Fed speakers coming up on Wednesday. The times listed below are in GMT / US Eastern time format:1600 /1200 Federal Reserve Board Governor...
October 18, 2023, 3:00 am
European equities close mixed in tuesday trading; thermo fisher acquires sweden’s olink for $3.6 billion
European stock markets closed mixed in Tuesday trading as the Stoxx Europe 600 eased 0.10%, the Swiss Market Index dropped 0.69%, France’s CAC gaine...
October 17, 2023, 11:59 pm
Off the record: silver looks better than gold in 2024 according to lbma survey
(Kitco News) - Although the Federal Reserve is expected to maintain interest rates at restrictive levels through most of 2024, geopolitical uncertaint...
October 17, 2023, 1:29 pm
Fmls:23 speaker spotlight – who drives the future of the payments landscape?
The collision between innovation and regulation has spilled into numerous verticals in 2023, namely the payments space. This long-brewing dynamic will...
October 17, 2023, 8:27 am
Bitcoin gives up gains after blackrock denies etf approval report
By Tom Wilson, Elizabeth Howcroft and Hannah Lang london/WASHINGTON (Reuters) -Bitcoin rose suddenly on...
October 16, 2023, 3:44 pm
Exlusive: why abcam founder believes danaher's acquisition offer falls short
In an exclusive interview with Thomas Warner (TW) of Proactive london, Dr Jonathan Milner (JM), the fou...
October 16, 2023, 8:46 am
Bank of england chief economist huw pill speaks today - finely balanced again?
0830 GMT / 0430 US Eastern time: Bank of England Chief Economist Huw Pill speaks at an economic conference in ...
October 16, 2023, 2:56 am
Ultragenyx and mereo biopharma announce interim phase 2 data from phase 2/3 orbit study demonstrating setrusumab (ux143) significantly reduced fracture rates in patients with osteogenesis imperfecta (
Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annualized fracture rate associated with continuous a...
October 14, 2023, 8:30 pm
Ultragenyx and mereo biopharma announce interim phase 2 data from phase 2/3 orbit study demonstrating setrusumab (ux143) significantly reduced fracture rates in patients with osteogenesis imperfecta (
Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annualized fracture rate associated with continuous a...
October 14, 2023, 8:30 pm
Ultragenyx and mereo biopharma announce interim phase 2 data from phase 2/3 orbit study demonstrating setrusumab (ux143) significantly reduced fracture rates in patients with osteogenesis imperfecta (
Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annualized fracture rate associated with continuous a...
October 14, 2023, 8:30 pm
Ultragenyx and mereo biopharma announce interim phase 2 data from phase 2/3 orbit study demonstrating setrusumab (ux143) significantly reduced fracture rates in patients with osteogenesis imperfecta (
Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annualized fracture rate associated with continuous a...
October 14, 2023, 8:30 pm
Ultragenyx and mereo biopharma announce interim phase 2 data from phase 2/3 orbit study demonstrating setrusumab (ux143) significantly reduced fracture rates in patients with osteogenesis imperfecta (
Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annualized fracture rate associated with continuous a...
October 14, 2023, 8:30 pm
Ultragenyx and mereo biopharma announce interim phase 2 data from phase 2/3 orbit study demonstrating setrusumab (ux143) significantly reduced fracture rates in patients with osteogenesis imperfecta (
Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annualized fracture rate associated with continuous a...
October 14, 2023, 8:30 pm
Ultragenyx and mereo biopharma announce interim phase 2 data from phase 2/3 orbit study demonstrating setrusumab (ux143) significantly reduced fracture rates in patients with osteogenesis imperfecta (
Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annualized fracture rate associated with continuous a...
October 14, 2023, 8:30 pm
Ultragenyx and mereo biopharma announce interim phase 2 data from phase 2/3 orbit study demonstrating setrusumab (ux143) significantly reduced fracture rates in patients with osteogenesis imperfecta (
Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annualized fracture rate associated with continuous a...
October 14, 2023, 8:30 pm
Ultragenyx and mereo biopharma announce interim phase 2 data from phase 2/3 orbit study demonstrating setrusumab (ux143) significantly reduced fracture rates in patients with osteogenesis imperfecta (
Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annualized fracture rate associated with continuous a...
October 14, 2023, 8:30 pm
Ultragenyx and mereo biopharma announce interim phase 2 data from phase 2/3 orbit study demonstrating setrusumab (ux143) significantly reduced fracture rates in patients with osteogenesis imperfecta (
Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annualized fracture rate associated with continuous a...
October 14, 2023, 8:30 pm
Ultragenyx and mereo biopharma announce interim phase 2 data from phase 2/3 orbit study demonstrating setrusumab (ux143) significantly reduced fracture rates in patients with osteogenesis imperfecta (
Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annualized fracture rate associated with continuous a...
October 14, 2023, 8:30 pm
Ultragenyx and mereo biopharma announce interim phase 2 data from phase 2/3 orbit study demonstrating setrusumab (ux143) significantly reduced fracture rates in patients with osteogenesis imperfecta (
Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annualized fracture rate associated with continuous a...
October 14, 2023, 8:30 pm